You just read:

Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention

News provided by

Tarsa Therapeutics, Inc.

Feb 14, 2011, 07:30 ET